Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003074318 | SCV003454206 | uncertain significance | Deficiency of 3-hydroxyacyl-CoA dehydrogenase | 2022-04-18 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with tyrosine, which is neutral and polar, at codon 166 of the HADH protein (p.Phe166Tyr). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with HADH-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004978527 | SCV005590017 | uncertain significance | Inborn genetic diseases | 2024-07-02 | criteria provided, single submitter | clinical testing | The c.497T>A (p.F166Y) alteration is located in exon 4 (coding exon 4) of the HADH gene. This alteration results from a T to A substitution at nucleotide position 497, causing the phenylalanine (F) at amino acid position 166 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |